Positive Phase 1/2a and 72-Week OLE Data Reported Across Oral Amylin and GLP-1 Programs
GPCR has more than doubled off its 52-week low of $19.5 on light trading volume (0.4× avg).
Summary
Positive clinical data for both lead obesity programs was reported by Structure Therapeutics: ACCG-2671 showed promising Phase 1/2a SAD results with a ~6-day half-life, and aleniglipron demonstrated up to 16.2% weight loss at 72 weeks with no plateau.
Key Events · Product Development and Regulatory · GPCR
-
ACCG-2671 Phase 1/2a SAD Data Positive
First-in-class oral amylin agonist showed ~6-day half-life supporting once-weekly dosing, no SAEs, and 3.3% mean weight loss after a single 10 mg dose in healthy participants.
-
Aleniglipron 72-Week OLE Results
Up to 16.2% body weight loss at 180 mg with no plateau; 36% of top-dose participants achieved ≥20% weight loss; <5% AE-related discontinuations.
-
Phase 3 ACCOMPLISH Program Underway
Two registrational trials enrolling up to 4,700 participants total (3,600 in ACCOMPLISH-1, 1,100 in ACCOMPLISH-2); topline data expected in 2H 2028.
-
Cash Runway Through 2028
~$1.3B in cash as of June 30, 2026 expected to fund the aleniglipron Phase 3 program through 2028.
Analysis · GPCR · Life Sciences
Positive clinical data across both lead obesity programs was delivered by Structure Therapeutics. ACCG-2671, a first-in-class oral amylin agonist, showed a ~6-day half-life supporting once-weekly dosing, no serious adverse events, and 3.3% single-dose weight loss — early evidence of target engagement. Aleniglipron's 72-week ACCESS OLE results showed up to 16.2% weight loss with no plateau, 36% of top-dose participants achieving ≥20% weight loss, and improved tolerability with a 2.5 mg starting dose. The company also confirmed ~$1.3B in cash to fund Phase 3 through 2028, with topline data expected in 2H 2028. This data package strengthens the case for aleniglipron as a potential best-in-class oral GLP-1 and validates ACCG-2671 as a differentiated amylin asset.
How filings like this one have moved
In the 30 days to Sep 10, 2026, 35.8% of the 1864 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, GPCR was trading at $47.60 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $3.4B. The 52-week trading range was $19.50 to $94.90. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.